Biblio

Export 372 results:
[ Author(Desc)] Keyword Title Type Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
M. Grassi, Perna, G., Caldirola, D., Schruers, K., Duara, R., and Loewenstein, D. A., “A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1555-1573, 2018.
A. Griciuc, Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. Hoon, Hyman, B. T., and Tanzi, R. E., “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
R. Guerreiro, Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J. - C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., and Hardy, J., “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
F. Guillot, Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., and Davis, S., “Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.
B. Gurel, Cansev, M., Sevinc, C., Kelestemur, S., Ocalan, B., Cakir, A., Aydin, S., Kahveci, N., Ozansoy, M., Taskapilioglu, O., Ulus, I. Hakki, Başar, M. Karayel, Sahin, B., Tuzuner, M. Bora, and Baykal, A. Tarik, “Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1399-1410, 2018.
H
M. El Haj, Coello, Y., Kapogiannis, D., Gallouj, K., and Antoine, P., “Negative Prospective Memory in Alzheimer's Disease: "Do Not Perform That Action".”, J Alzheimers Dis, vol. 61, no. 2, pp. 663-672, 2018.
I. Hallikainen, Hongisto, K., Välimäki, T., Hänninen, T., Martikainen, J., and Koivisto, A. M., “The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1367-1376, 2018.
H. Hampel, Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., Chiesa, P. A., Colliot, O., Coman, C. - M., Dubois, B., Duggento, A., Durrleman, S., Ferretti, M. - T., George, N., Genthon, R., Habert, M. - O., Herholz, K., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T., Lehéricy, S., Lorenceau, J., Neri, C., Nisticò, R., Nyasse-Messene, F., Ritchie, C., Rossi, S., Santarnecchi, E., Sporns, O., Verdooner, S. R., Vergallo, A., Villain, N., Younesi, E., Garaci, F., and Lista, S., “Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.”, J Alzheimers Dis, vol. 64, no. s1, pp. S47-S105, 2018.
F. T. Hane, Robinson, M., Lee, B. Y., Bai, O., Leonenko, Z., and Albert, M. S., “Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.”, J Alzheimers Dis, vol. 57, no. 3, pp. 645-665, 2017.
R. Harris, Miners, J. Scott, Allen, S., and Love, S., “VEGFR1 and VEGFR2 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 741-752, 2018.
Y. Hasegawa, Toyama, K., Uekawa, K., Ichijo, H., and Kim-Mitsuyama, S., “Role of ASK1/p38 Cascade in a Mouse Model of Alzheimer's Disease and Brain Aging.”, J Alzheimers Dis, vol. 61, no. 1, pp. 259-263, 2018.
A. Hatami, Monjazeb, S., and Glabe, C., “The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils.”, J Alzheimers Dis, vol. 50, no. 2, pp. 517-25, 2016.
S. Hatashita and Wakebe, D., “Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.”, J Alzheimers Dis, vol. 57, no. 3, pp. 765-773, 2017.
X. - Y. He, Isaacs, C., and Yang, S. - Y., “Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 665-673, 2018.
G. He, Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P., and Greengard, P., “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
J. Heinrich, Vidal, J. - S., Simon, A., Rigaud, A. - S., Hanon, O., Epelbaum, J., Viollet, C., and Duron, E., “Relationships Between Lower Olfaction and Brain White Matter Lesions in Elderly Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1133-1141, 2018.
K. Hensley and Kursula, P., “Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.”, J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
P. Heßmann, Seeberg, G., Reese, J. Peter, Dams, J., Baum, E., Müller, M. J., Dodel, R., and Balzer-Geldsetzer, M., “Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings.”, J Alzheimers Dis, vol. 51, no. 2, pp. 545-61, 2016.
H. Hochstetler, Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., Degenhardt, E., Leoutsakos, J. - M., and Lyketsos, C. G., “Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”, J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G., “Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
A. Homma, Atarashi, H., Kubota, N., Nakai, K., and Takase, T., “Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 345-57, 2016.
F. Huang, Shang, Y., Luo, Y., Wu, P., Huang, X., Tan, X., Lu, X., Zhen, L., and Hu, X., “Lower Prevalence of Alzheimer's Disease among Tibetans: Association with Religious and Genetic Factors.”, J Alzheimers Dis, vol. 50, no. 3, pp. 659-67, 2016.
C. M. Huber, Yee, C., May, T., Dhanala, A., and Mitchell, C. S., “Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.”, J Alzheimers Dis, vol. 61, no. 1, pp. 265-281, 2018.
B. T. Hyman, Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., Nelson, P. T., Schneider, J. A., Thal, D. Rudolf, Thies, B., Trojanowski, J. Q., Vinters, H. V., and Montine, T. J., “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
I
M. Ibarria, Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., Tantinyá, N., Vera, M., Hernandez, I., Becker, J. T., Ruiz, A., Boada, M., and Tárraga, L., “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.

Pages